Share

Pfizer lifts outlook on higher oncology, vaccine sales

New York - Pfizer reported better-than-expected earnings on Tuesday, as strong sales in oncology and vaccines offset a hit from patent expirations.

The pharma giant reported third-quarter earnings of $2.1bn, down 20.1% from the year-ago period.

Revenues were $12.09bn, down 2.2% from the year-ago period, in part due to the impact from the strong dollar.

Pfizer notched strong sales gains in its innovative products business, which includes global vaccines and global oncology, two divisions with strong increases.

Other outperformers included global sales of the stroke-reduction drug Eliquis, US sales of Lyrica, which is used to treat nerve pain, and of the rheumatoid arthritis drug Xeljanz in the US.

On the downside, sales for Pfizer's other major division, established products, fell 16.3% from the year-ago period to $5.2bn.

The decline was partly due to the loss exclusivity for some key drugs, including pain-killer Celebrex and the antibiotic Zyvox.
 
"Our research pipeline continues to advance with a focus on therapeutic areas of high unmet need," said Pfizer chief executive Ian Read, adding that recent advances "could support the development of potential important new therapies to further strengthen our innovative products business."

Adjusted earnings for the third quarter translated to 60 cents per share, better than the 51c analyst estimate. Revenues also topped the $11.56bn analyst estimate by about $530m.

Pfizer raised some of its 2015 forecasts, including its 2015 sales to $47.5-$48.5bn and adjusted earnings of $2.16-$2.20.

The prior estimates were for sales of $46.5 to $47.5bn and adjusted earnings of $2.04 to $2.10 per shares.

Shares of Dow member Pfizer rose 3.1% to $35.22 in pre-market trade.


We live in a world where facts and fiction get blurred
Who we choose to trust can have a profound impact on our lives. Join thousands of devoted South Africans who look to News24 to bring them news they can trust every day. As we celebrate 25 years, become a News24 subscriber as we strive to keep you informed, inspired and empowered.
Join News24 today
heading
description
username
Show Comments ()
Rand - Dollar
19.00
-0.5%
Rand - Pound
24.02
-0.5%
Rand - Euro
20.51
-0.2%
Rand - Aus dollar
12.35
-0.0%
Rand - Yen
0.13
-0.6%
Platinum
900.15
+0.4%
Palladium
1,000.00
-0.2%
Gold
2,210.45
+0.7%
Silver
24.60
-0.2%
Brent Crude
86.09
-0.2%
Top 40
68,142
+0.7%
All Share
74,329
+0.6%
Resource 10
56,957
+2.3%
Industrial 25
103,635
+0.4%
Financial 15
16,485
-0.2%
All JSE data delayed by at least 15 minutes Iress logo
Company Snapshot
Editorial feedback and complaints

Contact the public editor with feedback for our journalists, complaints, queries or suggestions about articles on News24.

LEARN MORE
Government tenders

Find public sector tender opportunities in South Africa here.

Government tenders
This portal provides access to information on all tenders made by all public sector organisations in all spheres of government.
Browse tenders